Partially consistent with our finding, accumulating evidence has demonstrated that BCL9 was upregulated in numerous malignancies as a consequence of the downregulation of tumor-suppressing microRNAs which negatively mediated BCL9, such as miR-30c-2* in ovarian cancer [26], miR-30a in gastric cancer [27], and miR-1301 in hepatocellular carcinoma [28]. This evidence concerns the gene BCL9 and hepatocellular carcinoma.